FDA Inspection
Novacyl Wuxi Pharmaceutical Co., Ltd.Novacyl Wuxi Pharmaceutical Co., Ltd. – FDA Inspection, Apr 14, 2016
Record Details
This FDA Inspection record concerns Novacyl Wuxi Pharmaceutical Co., Ltd., with an inspection on April 14, 2016, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- April 14, 2016
- Product Type
- Drugs
View Company Profile
ID · 2229d702-8259-41c1-a77d-0cff43730a0f
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 965700
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of Novacyl Wuxi Pharmaceutical Co., Ltd.
3| Date | Classification | Office | Project area |
|---|---|---|---|
| September 15, 2017 | Not classified | Office of Inspections and Investigations | |
| October 18, 2013 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 21, 2011 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Novacyl Wuxi Pharmaceutical Co., Ltd.
- FDA Inspection 1029764 - 2017-09-15
- FDA Inspection 853505 - 2013-10-18
- FDA Inspection 735469 - 2011-04-21
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.